NCT03331640 - A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 2, 2018

Primary Completion Date

September 13, 2021

Study Completion Date

September 13, 2021

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

OFF

"OFF:~5-FU 2000 mg/m2 as 24 hour infusion + Na folinic acid 200 mg/m2 on D1, 8, 15, 22 Oxaliplatin 85 mg/m2 on D8, 22 3 weeks rest after D22; Cycle q42d"

DRUG

FOLFIRI Protocol

Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion Na folinic acid 200 mg/m2 Cycle q2w

Trial Locations (1)

Unknown

Praxis für Innere Medizin, Friedrichshafen